Kenneth Smith

Of the 17 analysts covering Thermo Fisher Scientific (TMO), 14 recommend ” buy” or a higher rating, and three recommend “hold.”

In fiscal 2018 and fiscal 2019, Thermo Fisher Scientific (TMO) is expected to generate revenue of $24.08 billion and $25.19 billion, respectively, compared with revenue of $20.92 billion in fiscal 2017.

In this series, we’ll explore Thermo Fisher’s financials and valuation, and analysts’ views on its stock.

Of the 11 analysts covering BeiGene (BGNE), four have given it “strong buys,” and seven have given it “buys.”

BeiGene is a company focused on bringing to market molecularly targeted and immuno-oncology drugs for the treatment of cancer.

In this year’s second quarter, Abiomed’s (ABMD) net investment income rose YoY (year-over-year) to $1.67 million from $781,000.

In the second quarter of 2018, Abiomed’s (ABMD) cost of revenue rose YoY (year-over-year) to $29.85 million.

In this series, we’ll explore Abiomed’s financials and valuation along with analysts’ views on its stock.

Sarepta Therapeutics’ (SRPT) R&D (research and development) expenses rose YoY (year-over-year) to $86.58 million.

Kalydeco, Orkambi, and Symdeko are Vertex Pharmaceuticals’ (VRTX) products on the market.

Of the 25 analysts covering Vertex Pharmaceuticals (VRTX), 21 recommend “buy” or a higher rating, and four recommend “hold.”

Vertex Pharmaceuticals (VRTX) focuses on developing cystic fibrosis therapies and bringing them to market.

In this year’s third quarter, bluebird bio (BLUE) generated net interest income of $4.59 million.

In 2018 and 2019, bluebird bio (BLUE) is expected to generate revenues of $43.62 million and $67.0 million, respectively.

In the third quarter, bluebird bio’s total revenue rose YoY (year-over-year) to $11.53 million from $7.71 million.

The Zulresso injection is Sage Therapeutics’ lead product candidate. The company has filed a new drug application.

In fiscal 2018 and fiscal 2019, Sage Therapeutics (SAGE) is expected to generate revenues of $79.41 million and $36.63 million, respectively.

Of the 14 analysts covering Ionis Pharmaceuticals (IONS), five have given it “buy” or higher ratings, seven have given it “holds.”

Ionis Pharmaceuticals’ (IONS) two business segments are Ionis Core and Akcea Therapeutics, in which Ionis holds a 76% stake.

In the third quarter, DaVita’s total revenue rose YoY (year-over-year) to $2.85 billion from $2.76 billion.

Of the 29 analysts covering Biogen (BIIB), 20 have given it “buy” or higher ratings, and nine have given it “hold” ratings.

In the third quarter, Biogen’s net product revenue rose year-over-year to $2.78 billion from $2.62 billion.

In fiscal 2018 and fiscal 2019, Abbott Laboratories (ABT) is expected to generate revenue of $30.66 billion and $32.21 billion, respectively, compared with revenue of $27.39 billion in fiscal 2017.

Abbott Laboratories (ABT) offers products in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Cardiovascular and Neuromodulation Products.

Of the 26 analysts covering Regeneron Pharmaceuticals (REGN), eight recommend “buy” or a higher rating, 17 recommend “hold,” and one recommends “sell.”

In fiscal 2018 and fiscal 2019, Regeneron Pharmaceuticals (REGN) is expected to generate revenue of $6.49 billion and $7.16 billion, respectively, compared with revenue of $5.87 billion in fiscal 2017.

In December 2018, of the total 13 analysts covering Seattle Genetics, eight analysts have given Seattle Genetics stock a “buy” or higher rating.

Seattle Genetics generated total revenues of $169.42 million in the third quarter of 2018 as compared with $135.29 million in the comparable period of 2017.

In December 2018, of the total 16 analysts covering Endo International (ENDP), five analysts have given Endo stock a “buy” or higher rating and 11 analysts have given it a “hold” rating.

After a phenomenal run from $2.52 on January 5 to a high of $51.17 on September 13, Tandem Diabetes Care (TNDM) stock slid.

From a low of $376.92 on January 4, Intuitive Surgical (ISRG) stock rose to a high of $581.12 on October 1.

After witnessing a rise from $209.54 on February 8 to a high of $372.61 on September 28, Illumina (ILMN) stock corrected to $289.50 on October 24.

Dentsply Sirona stock witnessed a steady uptick in November, rising from $34.58 on November 6 to $37.78 on November 30.

After rising from $36.53 on April 9, 2018, to $42.91 on July 31, 2018, Hologic (HOLX) stock slid to $37.90 on October 29, 2018.

After witnessing strong gains from $115.41 on January 4, 2018, to a high of $174.10 on September 28, 2018.

In December 2018, of the total 15 analysts covering Align Technology, 13 analysts have given the stock a “buy” or higher rating.

In this series, we explore Sangamo’s financials, analysts’ views on the stock, and the company’s valuation metrics.

Array BioPharma generated total revenue of $56.91 million in the first quarter of fiscal 2019.

In November, of the 19 analysts covering Illumina (ILMN), 14 have given it “buy” or higher ratings, and five have given it “hold” ratings.

Illumina’s cost of product revenue increased from $173.0 million in the third quarter of 2017 to $184.0 million in the third quarter of 2018.

For 2018 and 2019, Illumina is expected to generate revenues of $3.33 billion and $3.80 billion, respectively.

A strong operational performance and steady uptick in Edwards Lifesciences’ stock price has kept investors interested in the stock in 2018.

Dentsply Sirona’s interest expense decreased marginally from $9.8 million in the third quarter of 2017 to $9.7 million in the third quarter.

In November 2018, of the total 20 analysts covering Hologic (HOLX), ten analysts have given the stock a “buy” or higher rating, and ten analysts have given it a “hold” rating.

For fiscal 2019 and 2020, Hologic (HOLX) is expected to generate total revenues of $3.32 billion and $3.45 billion, respectively.

In November, of the total 15 analysts covering Zoetis (ZTS), 12 analysts have given the stock “buy” or higher ratings.

In November, of the total 21 analysts covering Tesaro (TSRO) stock, 13 have given it “buy” or higher ratings, and eight have given it “hold” ratings.

In November 2018, of the total 29 analysts covering Stryker (SYK), 19 analysts gave Stryker stock a “buy” or higher rating, and ten analysts have given it a “hold” rating.

Stryker’s (SYK) net other expense decreased from $54.0 million in the third quarter of 2017 to $42.0 million in the latest quarter.

Stryker generated total revenues of $3.24 billion in the third quarter of 2018 as compared to $3.01 billion in the comparable period of 2017.

Fluctuations in Baxter International’s (BAX) stock price have kept investors interested in the stock in 2018.

In November, among the ten analysts covering Editas Medicine (EDIT), six analysts recommended a “buy,” while four recommended a “hold.”

In November, of the 12 analysts covering Clovis Oncology (CLVS) stock, seven have given it “buy” or higher ratings, and five have given it “hold” ratings.

Clovis Oncology generated total revenue of $22.76 million in the third quarter compared to $16.81 million in the comparable period of 2017.

This month, of the total ten analysts covering Tandem Diabetes Care (TNDM), seven have given the stock a “buy” or higher rating and three have given it a “hold” rating.

Tandem Diabetes Care’s (TNDM) key focus is its t:slim X2 insulin delivery system, which is designed to display continuous glucose monitoring directly on a pump’s home screen.

In this series, we’ll explore TransEnterix’s financials, analyst recommendations, and valuation metrics.

Nektar Therapeutics generated total revenues of $27.76 million in the third quarter of 2018 as compared with $152.93 million in the third quarter of 2017.

In November 2018, of the total 18 analysts covering Alexion Pharmaceuticals (ALXN), 16 analysts have given the stock a “buy” or higher rating, and two analysts have given it a “hold” rating.

Alexion Pharmaceuticals’ (ALXN) key products on the market include Soliris, Strensiq, and Kanuma.

In November, six analysts recommended a “strong buy,” ten recommended a “buy,” and 12 recommended a “hold” for Gilead Sciences.

Gilead Sciences’ HIV product sales in the United States increased from $2.52 billion in the third quarter of 2017 to $3.0 billion in the third quarter.

Gilead Sciences’ (GILD) interest expense decreased from $291.0 million in the third quarter of 2017 to $264.0 million in the third quarter.

The sales of Bristol-Myers Squibb’s Baraclude fell from $264.0 million in the third quarter of 2017 to $175.0 million in the third quarter of 2018.

Bristol-Myers Squibb (BMY) reported its third quarter of fiscal 2018 results on October 25. Its total revenues increased to $5.69 billion.

Varian Medical Systems reported net income of $116.8 million in the fourth quarter of fiscal 2018 as compared to $78.6 million in the fourth quarter of fiscal 2017.

Alexion Pharmaceuticals (ALXN) is scheduled to report its third-quarter earnings on October 24.

Of the total 28 analysts covering Stryker (SYK) in October 2018, 19 analysts have given the stock a “buy” or higher rating, and nine analysts have given Stryker a “hold” rating.

Of the five analysts covering NovoCure (NVCR) stock in October, two have given it a “strong buy,” and three have given it a “buy.”

Boston Scientific (BSX) is expected to report its third-quarter earnings on October 24.

Varian Medical Systems (VAR) is expected to report net income of $105.05 million in the fourth quarter of fiscal 2018.

Varian Medical Systems (VAR) is expected to report its earnings for the fourth quarter of fiscal 2018 on October 23.

Sarepta is expected to incur R&D expenses of $277.8 million in fiscal 2018, compared with $166.71 million in fiscal 2017.

Sarepta Therapeutics’ revenues are forecast to be $302.13 million in 2018 and $430.37 million in 2019, up from $154.58 million in 2017.

After its stellar rise from $54.02 on January 8 to a high of $161.51 on September 28, Sarepta stock has seen selling pressure amid the market volatility in October.

Vertex announced on October 10 that the FDA has lifted the clinical hold and accepted its Investigational New Drug Application for CTX001.

In September, Alexion Pharmaceuticals agreed to acquire Syntimmune, a clinical stage biotechnology company.

Intuitive Surgical’s (ISRG) cost of goods sold is expected to rise 16.82% to $265.76 million in the third quarter of 2018.

Intuitive Surgical (ISRG) is expected to report its third-quarter earnings results on October 18.

On October 3, Gilead Sciences (GILD) reported the results from a phase three study evaluating Biktarvy’s safety and efficacy.

In October, 18 analysts gave Gilead Sciences stock a “buy” or higher rating, while ten analysts gave the stock a “hold” rating.

For Gilead Sciences (GILD), falling revenues and recent gains in the stock price have kept investors interested in the stock.

Seattle Genetics (SGEN) incurred a cost of sales of $13.16 million in the second quarter—compared to $8.06 million in the second quarter of 2017.

Seattle Genetics (SGEN) is focused on maximizing Adcetris’ market reach. Currently, the product is sold in 71 countries.

Seattle Genetics acquired clinical-stage biopharmaceutical company Cascadian in March for $614.1 million at $10.0 per share.

Seattle Genetics generated total revenues of $170.17 million in the second quarter—compared to $108.22 million in the same period in 2017.

In October, of the seven analysts covering Viking Therapeutics, one has given its stock a “strong buy” rating.

Viking Therapeutics’ product candidate VK2809 is undergoing a Phase 2 trial for the treatment of patients with hypercholesterolemia and fatty liver disease.

In this series, we’ll analyze three pharmaceutical companies with focused nonalcoholic steatohepatitis pipelines.

In September, of the seven analysts covering ViewRay (VRAY), six have given its stock “buy” or higher ratings, and one analyst has given it a “sell” rating.

ViewRay incurred general and administrative expenses of $10.5 million in the second quarter compared to $7.46 million in the second quarter of 2017.

The mean rating for ResMed (RMD) stock is 2.6, and its target price is $104.69.

ResMed (RMD) generated revenues of $2.34 billion in fiscal 2018, compared with revenues of $2.07 billion in fiscal 2017.

In September, of the 15 analysts covering Waters Corporation (WAT) stock, ten have given it “holds.”

Waters Corporation (WAT) incurred selling and administrative expenses of $136.6 million in the second quarter.

In the last three months, Agilent Technologies (A) stock has risen from $61.14 on June 27, 2018, to $70.33 in September 2018.

Agilent Technologies’ (A) Life Sciences and Applied Markets segment had revenues of $510 million in Q3 2017 compared to $540 million in Q3 2018.

Agilent Technologies (A) incurred selling, general, and administrative expenses of $339 million in the third quarter of 2018.

Agilent Technologies (A) has been on an acquisition spree in 2018 with major acquisitions made until the third quarter.

Of the seven analysts covering Verastem (VSTM) in September, two have given the stock a “strong buy” rating, and five have given it a “buy.”